Skip to content

It takes more than medicine...

DONATE
 
  • Instagram
  • Vimeo
  • Linkedin

8607 Roberts Drive, Suite 150 Sandy Springs, GA 30350-2237

(770) 518-8272phone    (770) 518-3310fax

8607 Roberts Drive, Suite 150 Sandy Springs, GA 30350-2237

menu
 
 
graphic of dna strand

FDA Delays Roll Out of First Hemophilia Gene Therapy

By Tracy Heath, Director of Communications

Published September 9, 2020

 

Unexpectedly, the U.S. Food and Drug Administration did not approve BioMarin’s gene therapy for severe hemophilia A in August. The FDA is requiring the company to conduct more research to determine how long the therapy’s results last. The FDA is asking for two years of follow-up data which will not be complete until November 2021.  

Other drug companies are developing gene therapies for hemophilia A, but they are not as far along in testing. The companies include partnerships between Pfizer Inc. and Sangamo Therapeutics and Spark Therapeutics and Generation Bio.